Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) has issued an announcement.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has entered into a BOC Structured Deposit Agreement to subscribe for a wealth management product with a principal amount of RMB440 million. This transaction is classified as a discloseable transaction under the Listing Rules, requiring reporting and announcement due to its percentage ratio exceeding 5% but being less than 25%. The structured deposit is principal-guaranteed with a floating return, set to mature on March 31, 2026, with an expected annualized floating rate of return between 0.800% and 2.1620%.
The most recent analyst rating on (HK:6990) stock is a Hold with a HK$434.36 price target. To see the full list of analyst forecasts on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock, see the HK:6990 Stock Forecast page.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the biopharmaceutical industry. The company focuses on developing and providing biopharmaceutical products and services.
Average Trading Volume: 821,159
Technical Sentiment Signal: Buy
Current Market Cap: HK$113.4B
See more insights into 6990 stock on TipRanks’ Stock Analysis page.